BTN3A1 (CD277) Target: γδ T Cell Immune Recognition Mechanism and Cancer Immunotherapy Research Progress

1. Research Background and Biological Functions of BTN3A1 (CD277)

BTN3A1 first attracted attention due to its core role in the recognition of phosphoantigens (pAg) by Vγ9Vδ2 T cells. Studies have found that the anti-CD277 antibody 20.1 can mimic Vγ9Vδ2 T cell activation caused by intracellular pAg accumulation, while 103.2 can block the activation of Vγ9Vδ2 T cells by target cells after pAg or aminobisphosphonate treatment; combined with siRNA knockdown and domain substitution experiments, the related function was finally localized to the BTN3A1 subtype ^[1]. Meanwhile, FRAP experiments showed that intracellular pAg accumulation reduces the membrane mobility of BTN3A1, and this change is closely related to subsequent T cell activation, providing direct evidence for the model of "metabolic abnormality - membrane protein dynamics change - γδ TCR recognition" ^[1]. In addition, ABCA1 mediates the efflux of representative pAg—isopentenyl pyrophosphate (IPP), and the interaction between apoA-I and BTN3A1 may be involved in this process, suggesting that soluble IPP may also participate in signal transmission between target cells and Vγ9Vδ2 T cells, but its specific recognition mode remains unclear ^[2].

With further research, the functional localization of BTN3A1 has been further refined. BTN2A1 has been shown to directly bind to the Vγ9 chain-related region, constituting the initial contact for γδ TCR recognition, while BTN3A1 regulates the spatial proximity to BTN2A1 through its intracellular domain, stabilizing cell contact and amplifying pAg-dependent signals ^[3]. In tumor immunity, the synergistic effect of BTN3A1 and BTN2A1 has also been confirmed to be exploitable by antibodies to enhance γδ T cell killing of tumor cells and improve the function of tumor-specific αβ T cells ^[4]. However, the functional interpretation of the CD277/BTN3 family still needs to be cautious, as commonly used CD277 antibodies cannot distinguish between BTN3 subtypes, and different cell types have different expression of BTN3A1, BTN3A2, and BTN3A3, which may affect the conclusions of early blocking or agonist experiments ^[5]. In inflammatory diseases, BTN3A1 is upregulated on the surface of monocytes in psoriasis patients and accompanied by abnormal Vγ9Vδ2 T cell function, also suggesting that BTN3A1 is not only a pAg sensing molecule, but also an important node of immune regulation ^[6].

2. Structural Characteristics and Phosphoantigen (pAg) Recognition Mechanism of BTN3A1

The structural characteristics of BTN3A1 determine its function as an intracellular pAg sensing molecule. Its key region is the intracellular B30.2 (PRY/SPRY) domain, which forms a positively charged binding pocket that can accommodate negatively charged isoprenyl pyrophosphate molecules such as HMBPP and IPP; biochemical analysis, site-directed mutagenesis and binding experiments have shown that key residues such as H381 are critical for ligand recognition ^[7,8]. However, existing evidence suggests that simple "binding" is not sufficient to explain the antigen sensing function of BTN3A1. NMR, crystallography and molecular dynamics studies further indicate that truly antigenic pAg not only enters the B30.2 pocket, but also induces a global conformational change of the domain, and this allosteric response better explains the functional activation of γδ T cells than simple binding [9,10]. In addition, some ligands with similar binding affinity cannot effectively induce T cell responses, indicating that "binding ability" and "activation ability" are not completely equivalent ^[7]. Further structural studies have also found that regions adjacent to B30.2 and the juxtamembrane segment may participate in dimer formation and transmit intracellular conformational changes to the membrane region and extracellular region, thereby providing a basis for subsequent signal amplification ^[10-12].

How intracellular recognition is converted into an extracellular recognizable structure is one of the core questions in BTN3A1 research. Biochemical reconstitution, ITC and live-cell BRET experiments showed that pAg can induce the interaction between the intracellular regions of BTN3A1 and BTN2A1, and the integrity of the BTN2A1 juxtamembrane segment is critical for this process and subsequent IFNγ responses ^[13]. Recent cryo-EM studies further suggest that pAg-induced BTN3A1/BTN2A1 complex remodeling can promote BTN molecules to form a conformational architecture suitable for Vγ9Vδ2 TCR recognition ^[14]. Meanwhile, antibody blocking and engineered Fab spacing experiments also suggest that signal triggering does not depend on simple aggregation, but on precise geometric configuration and epitope exposure state ^[15]. Therefore, the more reasonable current understanding is that BTN3A1 is not just a passive "ligand binder", but a conformational sensor that translates intracellular metabolic abnormalities into recognizable signals on the membrane surface.

3. Molecular Regulatory Mechanism of Vγ9Vδ2 T Cell Activation Mediated by BTN3A1

3.1 pAg Promotes the Formation of BTN3A1/BTN2A1 Complex

During Vγ9Vδ2 T cell recognition, pAg is not just a soluble metabolite, but more like a "molecular glue". It is first sensed by the intracellular domain of BTN3A1, then promotes the formation of a heterologous complex between BTN3A1 and BTN2A1, and drives signal transmission from the inside to the outside of the cell. Structural and kinetic studies have shown that pAg can be located at the key position of the BTN3A1–BTN2A1 complex interface, stabilizing the intracellular contact between the two and promoting dynamic changes conducive to the appearance of outward conformations ^[16]. Genetic and cytological studies have further confirmed that BTN2A1 is an indispensable component in the pAg sensing pathway and can directly contact the Vγ9-related region, so the BTN3A1–BTN2A1 complex should be regarded as a functional whole rather than two independent molecules ^[17]. However, most current evidence still comes from truncated constructs or in vitro systems, and there is still a lack of direct observation of the dynamic behavior of full-length membrane proteins in the natural membrane environment ^[18].

3.2 Complex Recognition, Inside-Out Conduction and Regulatory Factors

Studies have shown that BTN2A1 and BTN3A1 together form the composite ligand required for Vγ9Vδ2 TCR recognition: BTN2A1 laterally contacts the TCR, while BTN3A1 provides another recognition epitope, and the complex formed by the two and its dynamic state determine the recognition efficiency ^[19]. From the perspective of the signal pathway, after pAg binds to the intracellular B30.2 (PRY/SPRY) domain of BTN3A1, it can trigger extracellular conformational changes through the "inside-out" method; this stimulation is highly consistent with the activation induced by anti-BTN3A antibodies in downstream phosphorylation events such as ZAP70, PLCγ2, Akt, NFκB, p38 and Erk ^[20,21]. In addition, the protein stability, membrane localization and subcellular trafficking of BTN3A1 also affect this process. Related studies suggest that transporters such as ABCG2 are associated with BTN3A-dependent activation, while BTN3A2 may regulate the trafficking and optimal activity of BTN3A1 ^[22,23]. Therefore, BTN3A1-mediated Vγ9Vδ2 T cell activation is not a single ligand binding event, but a process jointly regulated by complex assembly, membrane localization and intracellular delivery ^[19-23].

4. Immunomodulatory Bidirectionality and Multi-Pathway Functions of BTN3A1

BTN3A1 does not only serve Vγ9Vδ2 T cell recognition. Studies have found that pAg-stimulated γδ T cells can inhibit NK cell responses to "missing-self" targets in a BTN3A1-dependent, cell contact-dependent manner, accompanied by downregulation of NKG2D and NKp44, suggesting that BTN3A1 may be involved in the negative regulation between innate immune effector cells ^[24]. On the other hand, LSECtin binding to BTN3A1 inhibits human T cell proliferation and inflammatory factor production, and this inhibition can be partially reversed by anti-BTN3A1 antibodies, indicating that BTN3A1 can also act as a negative signal receptor on the cell surface ^[25].

In contrast, BTN3A1 also has a positive role in innate immunity. Studies have shown that BTN3A1 can form a complex with TBK1, and under nucleic acid stimulation, it is relocated to the perinuclear region through MAP4-controlled dynein-dependent transport, promoting the interaction between TBK1 and IRF3 and enhancing IFN-β production; knockdown of BTN3A1 impairs the type I interferon response of cells to cytoplasmic DNA or RNA ^[26]. This indicates that BTN3A1 has obvious functional bidirectionality: it can participate in inhibitory cell-cell contact signals and also act as an intracellular scaffold to promote antiviral pathway activation. Therefore, any future therapeutic design targeting BTN3A1 must fully consider its domain division, stimulation context and cell type differences.